{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T01:54:09Z","timestamp":1786586049504,"version":"build-2736575974"},"reference-count":229,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T00:00:00Z","timestamp":1633564800000},"content-version":"vor","delay-in-days":371,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["GNT1185600"],"award-info":[{"award-number":["GNT1185600"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013321","name":"Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences","doi-asserted-by":"publisher","award":["ZDSYS20190902093409851"],"award-info":[{"award-number":["ZDSYS20190902093409851"]}],"id":[{"id":"10.13039\/501100013321","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004752","name":"State Government of Victoria","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004752","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001108","name":"Ophthalmic Research Institute of Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.ymthe.2020.06.029","type":"journal-article","created":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T19:51:18Z","timestamp":1593546678000},"page":"2120-2138","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":70,"title":["Gene Therapy Intervention in Neovascular Eye Disease: A Recent Update"],"prefix":"10.1016","volume":"28","author":[{"given":"Fan-Li","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng-Yuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Fan","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang-Hui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vickie H.Y.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bang V.","family":"Bui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3379-724X","authenticated-orcid":false,"given":"Guei-Sheung","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2020.06.029_bib1","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/35025220","article-title":"Angiogenesis in cancer and other diseases","volume":"407","author":"Carmeliet","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2020.06.029_bib2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.22336\/rjo.2019.4","article-title":"Corneal neovascularization: updates on pathophysiology, investigations & management","volume":"63","author":"Sharif","year":"2019","journal-title":"Rom. J. Ophthalmol."},{"key":"10.1016\/j.ymthe.2020.06.029_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1350-9462(02)00043-5","article-title":"Vascular endothelial growth factors and angiogenesis in eye disease","volume":"22","author":"Witmer","year":"2003","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.ymthe.2020.06.029_bib4","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00109-013-0993-5","article-title":"Ocular neovascularization","volume":"91","author":"Campochiaro","year":"2013","journal-title":"J.\u00a0Mol. Med. (Berl.)"},{"key":"10.1016\/j.ymthe.2020.06.029_bib5","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1146\/annurev-vision-082114-035439","article-title":"Angiogenesis and eye disease","volume":"1","author":"Usui","year":"2015","journal-title":"Annu. Rev. Vis. Sci."},{"key":"10.1016\/j.ymthe.2020.06.029_bib6","doi-asserted-by":"crossref","first-page":"e1221","DOI":"10.1016\/S2214-109X(17)30393-5","article-title":"Global causes of blindness and distance vision impairment 1990\u20132020: a systematic review and meta-analysis","volume":"5","author":"Flaxman","year":"2017","journal-title":"Lancet Glob. Health"},{"key":"10.1016\/j.ymthe.2020.06.029_bib7","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","article-title":"Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis","volume":"2","author":"Wong","year":"2014","journal-title":"Lancet Glob. Health"},{"key":"10.1016\/j.ymthe.2020.06.029_bib8","first-page":"CD005139","article-title":"Anti-vascular endothelial growth factor for neovascular age-related macular degeneration","volume":"3","author":"Solomon","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ymthe.2020.06.029_bib9","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0161-6420(93)31466-1","article-title":"Age-related macular degeneration histopathologic studies. The 1992 Lorenz E. Zimmerman Lecture","volume":"100","author":"Green","year":"1993","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ymthe.2020.06.029_bib10","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","article-title":"Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results","volume":"119","author":"Martin","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ymthe.2020.06.029_bib11","doi-asserted-by":"crossref","first-page":"E696","DOI":"10.1073\/pnas.1718059115","article-title":"CFH and ARMS2 genetic risk determines progression to neovascular age-related macular degeneration after antioxidant and zinc supplementation","volume":"115","author":"Vavvas","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2020.06.029_bib12","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1016\/j.ophtha.2013.07.039","article-title":"CFH and ARMS2 genetic polymorphisms predict response to antioxidants and zinc in patients with age-related macular degeneration","volume":"120","author":"Awh","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ymthe.2020.06.029_bib13","first-page":"377","article-title":"Current and emerging therapies for the treatment of age-related macular degeneration","volume":"2","author":"Emerson","year":"2008","journal-title":"Clin. Ophthalmol."},{"key":"10.1016\/j.ymthe.2020.06.029_bib14","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1159\/000499541","article-title":"Diabetic retinopathy in the context of patients with diabetes","volume":"62","author":"Sim\u00f3-Servat","year":"2019","journal-title":"Ophthalmic Res."},{"key":"10.1016\/j.ymthe.2020.06.029_bib15","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.diabres.2018.02.023","article-title":"IDF Diabetes Atlas: global estimates of diabetes prevalence for 2017 and projections for 2045","volume":"138","author":"Cho","year":"2018","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.ymthe.2020.06.029_bib16","doi-asserted-by":"crossref","first-page":"428","DOI":"10.4103\/0301-4738.100542","article-title":"The worldwide epidemic of diabetic retinopathy","volume":"60","author":"Zheng","year":"2012","journal-title":"Indian J. Ophthalmol."},{"key":"10.1016\/j.ymthe.2020.06.029_bib17","doi-asserted-by":"crossref","first-page":"556","DOI":"10.2337\/dc11-1909","article-title":"Global prevalence and major risk factors of diabetic retinopathy","volume":"35","author":"Yau","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ymthe.2020.06.029_bib18","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/s40273-019-00800-w","article-title":"Cost effectiveness of treatments for diabetic retinopathy: a systematic literature review","volume":"37","author":"Maniadakis","year":"2019","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.ymthe.2020.06.029_bib19","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/nyas.12412","article-title":"Diabetic retinopathy: loss of neuroretinal adaptation to the diabetic metabolic environment","volume":"1311","author":"Abcouwer","year":"2014","journal-title":"Ann. N Y Acad. Sci."},{"key":"10.1016\/j.ymthe.2020.06.029_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/CS20120588","article-title":"Advances in our understanding of diabetic retinopathy","volume":"125","author":"Stitt","year":"2013","journal-title":"Clin. Sci. (Lond.)"},{"key":"10.1016\/j.ymthe.2020.06.029_bib21","doi-asserted-by":"crossref","first-page":"F1000","DOI":"10.12688\/f1000research.19198.1","article-title":"Emerging therapies in the management of macular edema: a review","volume":"8","author":"Sacconi","year":"2019","journal-title":"F1000Res."},{"key":"10.1016\/j.ymthe.2020.06.029_bib22","doi-asserted-by":"crossref","first-page":"4940825","DOI":"10.1155\/2019\/4940825","article-title":"Oxidative stress and microvascular alterations in diabetic retinopathy: future therapies","volume":"2019","author":"Rodr\u00edguez","year":"2019","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.ymthe.2020.06.029_bib23","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/j.1600-0420.2006.00659.x","article-title":"Ocular angiogenesis: the role of growth factors","volume":"84","author":"Kvanta","year":"2006","journal-title":"Acta Ophthalmol. Scand."},{"key":"10.1016\/j.ymthe.2020.06.029_bib24","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1159\/000431129","article-title":"Ocular angiogenesis: vascular endothelial growth factor and other factors","volume":"55","author":"Rubio","year":"2016","journal-title":"Dev. Ophthalmol."},{"issue":"10S","key":"10.1016\/j.ymthe.2020.06.029_bib25","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1016\/j.ophtha.2016.04.056","article-title":"Anti-vascular endothelial growth factor agents in the treatment of retinal disease: from bench to bedside","volume":"123","author":"Campochiaro","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ymthe.2020.06.029_bib26","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/S0968-0004(03)00193-2","article-title":"VEGF-receptor signal transduction","volume":"28","author":"Cross","year":"2003","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.ymthe.2020.06.029_bib27","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1083\/jcb.200906044","article-title":"Anchorage of VEGF to the extracellular matrix conveys differential signaling responses to endothelial cells","volume":"188","author":"Chen","year":"2010","journal-title":"J.\u00a0Cell Biol."},{"key":"10.1016\/j.ymthe.2020.06.029_bib28","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1128\/MCB.06301-11","article-title":"A novel function of p38-regulated\/activated kinase in endothelial cell migration and tumor angiogenesis","volume":"32","author":"Yoshizuka","year":"2012","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.ymthe.2020.06.029_bib29","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/BCR.0b013e3181c7ed82","article-title":"Molecular mediators of angiogenesis","volume":"31","author":"Ucuzian","year":"2010","journal-title":"J.\u00a0Burn Care Res."},{"key":"10.1016\/j.ymthe.2020.06.029_bib30","doi-asserted-by":"crossref","first-page":"412","DOI":"10.2337\/dc16-2641","article-title":"Diabetic retinopathy: a position statement by the American Diabetes Association","volume":"40","author":"Solomon","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ymthe.2020.06.029_bib31","doi-asserted-by":"crossref","first-page":"e000249","DOI":"10.1136\/bmjophth-2018-000249","article-title":"Five-year outcomes of retinal vein occlusion treated with vascular endothelial growth factor inhibitors","volume":"4","author":"Spooner","year":"2019","journal-title":"BMJ Open Ophthalmol."},{"key":"10.1016\/j.ymthe.2020.06.029_bib32","doi-asserted-by":"crossref","first-page":"451","DOI":"10.3341\/kjo.2018.0011","article-title":"Anti-vascular endothelial growth factor treatment of retinopathy of prematurity: efficacy, safety, and anatomical outcomes","volume":"32","author":"Kang","year":"2018","journal-title":"Korean J. Ophthalmol."},{"key":"10.1016\/j.ymthe.2020.06.029_bib33","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1136\/bjophthalmol-2012-302137","article-title":"Subconjunctival bevacizumab induces regression of corneal neovascularisation: a pilot randomised placebo-controlled double-masked trial","volume":"97","author":"Petsoglou","year":"2013","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.ymthe.2020.06.029_bib34","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40942-019-0174-y","article-title":"Looking ahead in retinal disease management: highlights of the 2019 angiogenesis, exudation and degeneration symposium","volume":"5","author":"Puliafito","year":"2019","journal-title":"Int. J. Retina Vitreous"},{"key":"10.1016\/j.ymthe.2020.06.029_bib36","first-page":"485","article-title":"Clinical experience with pegaptanib sodium","volume":"2","author":"Rosina","year":"2008","journal-title":"Clin. Ophthalmol."},{"issue":"10, Suppl","key":"10.1016\/j.ymthe.2020.06.029_bib227","first-page":"S172","article-title":"Review of neovascular age-related macular degeneration treatment options","volume":"25","author":"Holekamp","year":"2019","journal-title":"Am. J. Manag. Care"},{"key":"10.1016\/j.ymthe.2020.06.029_bib44","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s40123-017-0083-9","article-title":"A review of ranibizumab for the treatment of diabetic retinopathy","volume":"6","author":"Stewart","year":"2017","journal-title":"Ophthalmol. Ther."},{"key":"10.1016\/j.ymthe.2020.06.029_bib56","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.2147\/OPTH.S184706","article-title":"Brolucizumab: evidence to date in the treatment of neovascular age-related macular degeneration","volume":"13","author":"Yannuzzi","year":"2019","journal-title":"Clin. Ophthalmol."},{"key":"10.1016\/j.ymthe.2020.06.029_bib228","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1023\/A:1007657109012","article-title":"Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer (NX1838) following injection into the vitreous humor of rhesus monkeys","volume":"17","author":"Drolet","year":"2000","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ymthe.2020.06.029_bib92","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1016\/j.ophtha.2008.04.023","article-title":"Vitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovascularization","volume":"115","author":"Zhu","year":"2008","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ymthe.2020.06.029_bib88","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.ajo.2012.03.047","article-title":"Intraocular pharmacokinetics of ranibizumab following a single intravitreal injection in humans","volume":"154","author":"Krohne","year":"2012","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.ymthe.2020.06.029_bib94","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1097\/IAE.0000000000002566","article-title":"Pharmacokinetic study of intravitreal aflibercept in humans with neovascular age-related macular degeneration","volume":"40","author":"Do","year":"2020","journal-title":"Retina"},{"key":"10.1016\/j.ymthe.2020.06.029_bib229","first-page":"695","article-title":"Ocular half-life of intravitreal biologics in humans and other species: meta-analysis and model-based prediction","volume":"17","author":"Caruso","year":"2020","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ymthe.2020.06.029_bib93","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s00417-013-2495-0","article-title":"Pharmacokinetics of bevacizumab after topical and intravitreal administration in human eyes","volume":"252","author":"Moisseiev","year":"2014","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"10.1016\/j.ymthe.2020.06.029_bib89","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1167\/iovs.12-10260","article-title":"Pharmacokinetics of ranibizumab in patients with neovascular age-related macular degeneration: a population approach","volume":"54","author":"Xu","year":"2013","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ymthe.2020.06.029_bib35","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1159\/000320007","article-title":"Antivascular endothelial growth factors in age-related macular degeneration","volume":"46","author":"Schmidt-Erfurth","year":"2010","journal-title":"Dev. Ophthalmol."},{"key":"10.1016\/j.ymthe.2020.06.029_bib37","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nrd1955","article-title":"Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease","volume":"5","author":"Ng","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2020.06.029_bib38","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ophtha.2016.09.012","article-title":"Incidence and growth of geographic atrophy during 5 years of comparison of age-related macular degeneration treatments trials","volume":"124","author":"Grunwald","year":"2017","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ymthe.2020.06.029_bib39","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1471-2415-12-37","article-title":"A retrospective, pooled data analysis of the safety of pegaptanib sodium in the treatment of age-related macular degeneration in subjects with or without diabetes mellitus","volume":"12","author":"Dombi","year":"2012","journal-title":"BMC Ophthalmol."},{"key":"10.1016\/j.ymthe.2020.06.029_bib40","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s40942-017-0084-9","article-title":"Retinal and choroidal angiogenesis: a review of new targets","volume":"3","author":"Cabral","year":"2017","journal-title":"Int. J. Retina Vitreous"},{"key":"10.1016\/j.ymthe.2020.06.029_bib41","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1006\/jmbi.1999.3192","article-title":"Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen","volume":"293","author":"Chen","year":"1999","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.ymthe.2020.06.029_bib42","doi-asserted-by":"crossref","first-page":"633.e1-4","DOI":"10.1016\/j.ophtha.2005.10.052","article-title":"Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I\/II multicenter, controlled, multidose study","volume":"113","author":"Heier","year":"2006","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ymthe.2020.06.029_bib43","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/j.1755-3768.2009.01576.x","article-title":"Significant improvements in near vision, reading speed, central visual field and related quality of life after ranibizumab treatment of wet age-related macular degeneration","volume":"88","author":"Frennesson","year":"2010","journal-title":"Acta Ophthalmol."},{"key":"10.1016\/j.ymthe.2020.06.029_bib45","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.mayocp.2012.12.007","article-title":"Off-label drug use: the bevacizumab story","volume":"88","author":"Stewart","year":"2013","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.ymthe.2020.06.029_bib46","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1080\/14728214.2017.1362390","article-title":"Emerging vascular endothelial growth factor antagonists to treat neovascular age-related macular degeneration","volume":"22","author":"Hussain","year":"2017","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"10.1016\/j.ymthe.2020.06.029_bib47","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3928\/1542-8877-20050701-14","article-title":"Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration","volume":"36","author":"Rosenfeld","year":"2005","journal-title":"Ophthalmic Surg. Lasers Imaging"},{"issue":"Suppl 1","key":"10.1016\/j.ymthe.2020.06.029_bib48","doi-asserted-by":"crossref","first-page":"i11","DOI":"10.1136\/bjophthalmol-2014-305302","article-title":"Safety profiles of anti-VEGF drugs: bevacizumab, ranibizumab, aflibercept and ziv-aflibercept on human retinal pigment epithelium cells in culture","volume":"98","author":"Malik","year":"2014","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.ymthe.2020.06.029_bib49","doi-asserted-by":"crossref","first-page":"25646","DOI":"10.1016\/S0021-9258(18)47298-5","article-title":"Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in\u00a0vitro and in\u00a0vivo, and high affinity binding to Flt-1 but not to Flk-1\/KDR","volume":"269","author":"Park","year":"1994","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ymthe.2020.06.029_bib50","doi-asserted-by":"crossref","first-page":"3186","DOI":"10.1167\/iovs.02-1092","article-title":"Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization","volume":"44","author":"Rakic","year":"2003","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ymthe.2020.06.029_bib51","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s10456-011-9249-6","article-title":"Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab","volume":"15","author":"Papadopoulos","year":"2012","journal-title":"Angiogenesis"},{"key":"10.1016\/j.ymthe.2020.06.029_bib52","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ymthe.2020.06.029_bib53","article-title":"Ziv-aflibercept: a cost-effective, off-label, highly potent antagonist of vascular endothelial growth factor","author":"Mansour","year":"2019","journal-title":"Acta Ophthalmol."},{"key":"10.1016\/j.ymthe.2020.06.029_bib54","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40942-016-0026-y","article-title":"Fusion proteins for treatment of retinal diseases: aflibercept, ziv-aflibercept, and conbercept","volume":"2","author":"de Oliveira Dias","year":"2016","journal-title":"Int. J. Retina Vitreous"},{"key":"10.1016\/j.ymthe.2020.06.029_bib55","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1007\/s40265-019-01231-9","article-title":"Brolucizumab: first approval","volume":"79","author":"Markham","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.ymthe.2020.06.029_bib57","first-page":"33","article-title":"Revision of the concept of anti-angiogenesis and its applications in tumor treatment","volume":"3","author":"Yang","year":"2017","journal-title":"Chronic Dis. Transl. Med."},{"key":"10.1016\/j.ymthe.2020.06.029_bib58","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1038\/nrc909","article-title":"VEGF and the quest for tumour angiogenesis factors","volume":"2","author":"Ferrara","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ymthe.2020.06.029_bib59","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s40842-017-0047-y","article-title":"Diabetic retinopathy: research to clinical practice","volume":"3","author":"Shah","year":"2017","journal-title":"Clin. Diabetes Endocrinol."},{"key":"10.1016\/j.ymthe.2020.06.029_bib60","first-page":"1857","article-title":"Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review","volume":"10","author":"Yang","year":"2016","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.ymthe.2020.06.029_bib61","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1080\/14740338.2019.1643838","article-title":"Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration: an update","volume":"18","author":"Costagliola","year":"2019","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.ymthe.2020.06.029_bib62","first-page":"1848","article-title":"Bevacizumab neutralizes the protective effect of vascular endothelial growth factor on retinal ganglion cells","volume":"16","author":"Brar","year":"2010","journal-title":"Mol. Vis."},{"key":"10.1016\/j.ymthe.2020.06.029_bib63","doi-asserted-by":"crossref","first-page":"4213","DOI":"10.1172\/JCI65157","article-title":"Targeted deletion of Vegfa in adult mice induces vision loss","volume":"122","author":"Kurihara","year":"2012","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2020.06.029_bib64","doi-asserted-by":"crossref","first-page":"3870","DOI":"10.1167\/iovs.07-1418","article-title":"Vascular endothelial growth factor mediates corneal nerve repair","volume":"49","author":"Yu","year":"2008","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ymthe.2020.06.029_bib65","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1080\/14656566.2019.1636031","article-title":"Innovative therapies for neovascular age-related macular degeneration","volume":"20","author":"Al-Khersan","year":"2019","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.ymthe.2020.06.029_bib66","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1080\/14712598.2018.1545836","article-title":"Diabetic retinopathy: a complex pathophysiology requiring novel therapeutic strategies","volume":"18","author":"Whitehead","year":"2018","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.ymthe.2020.06.029_bib67","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1111\/j.1582-4934.2008.00254.x","article-title":"Intra and extravascular transmembrane signalling of angiopoietin-1-Tie2 receptor in health and disease","volume":"12","author":"Makinde","year":"2008","journal-title":"J.\u00a0Cell. Mol. Med."},{"key":"10.1016\/j.ymthe.2020.06.029_bib68","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/376070a0","article-title":"Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation","volume":"376","author":"Sato","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2020.06.029_bib69","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/nrm2639","article-title":"Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system","volume":"10","author":"Augustin","year":"2009","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ymthe.2020.06.029_bib70","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1167\/iovs.14-13897","article-title":"Angiopoietin-1 suppresses choroidal neovascularization and vascular leakage","volume":"55","author":"Lee","year":"2014","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ymthe.2020.06.029_bib71","first-page":"1617","article-title":"Angiopoietin-1 upregulation by vascular endothelial growth factor in human retinal pigment epithelial cells","volume":"42","author":"Hangai","year":"2001","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ymthe.2020.06.029_bib72","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1126\/science.277.5322.55","article-title":"Angiopoietin-2, a natural antagonist for Tie2 that disrupts in\u00a0vivo angiogenesis","volume":"277","author":"Maisonpierre","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2020.06.029_bib73","first-page":"1912","article-title":"Expressions of angiopoietins and Tie2 in human choroidal neovascular membranes","volume":"40","author":"Otani","year":"1999","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ymthe.2020.06.029_bib74","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.ajo.2004.10.004","article-title":"Vitreous levels of angiopoietin 2 and vascular endothelial growth factor in patients with proliferative diabetic retinopathy","volume":"139","author":"Watanabe","year":"2005","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.ymthe.2020.06.029_bib75","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.15252\/emmm.201505889","article-title":"Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases","volume":"8","author":"Regula","year":"2016","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.ymthe.2020.06.029_bib76","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/s41433-019-0670-1","article-title":"Faricimab: expanding horizon beyond VEGF","volume":"34","author":"Sharma","year":"2020","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.ymthe.2020.06.029_bib77","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.ophtha.2019.03.023","article-title":"Simultaneous inhibition of angiopoietin-2 and vascular endothelial growth factor-A with faricimab in diabetic macular edema: BOULEVARD phase 2 randomized trial","volume":"126","author":"Sahni","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ymthe.2020.06.029_bib78","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1161\/01.RES.0000182903.16652.d7","article-title":"Endothelial\/pericyte interactions","volume":"97","author":"Armulik","year":"2005","journal-title":"Circ. Res."},{"key":"10.1016\/j.ymthe.2020.06.029_bib79","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1038\/s41467-017-01738-3","article-title":"Pericytes regulate VEGF-induced endothelial sprouting through VEGFR1","volume":"8","author":"Eilken","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2020.06.029_bib80","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1101\/gad.1653708","article-title":"Role of platelet-derived growth factors in physiology and medicine","volume":"22","author":"Andrae","year":"2008","journal-title":"Genes Dev."},{"key":"10.1016\/j.ymthe.2020.06.029_bib81","first-page":"553","article-title":"Antagonism of PDGF-BB suppresses subretinal neovascularization and enhances the effects of blocking VEGF-A","volume":"17","author":"Dong","year":"2014","journal-title":"Angiogenesis"},{"key":"10.1016\/j.ymthe.2020.06.029_bib82","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.2353\/ajpath.2006.050588","article-title":"Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization","volume":"168","author":"Jo","year":"2006","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ymthe.2020.06.029_bib83","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3928\/23258160-20170130-02","article-title":"An Overview of the Fovista and Rinucumab Trials and the Fate of Anti-PDGF Medications","volume":"48","author":"Dunn","year":"2017","journal-title":"Ophthalmic Surg. Lasers Imaging Retina"},{"key":"10.1016\/j.ymthe.2020.06.029_bib86","doi-asserted-by":"crossref","first-page":"365","DOI":"10.3390\/pharmaceutics11080365","article-title":"Pharmacokinetics of Intravitreal anti-VEGF drugs in age-related macular degeneration","volume":"11","author":"Garc\u00eda-Quintanilla","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ymthe.2020.06.029_bib87","first-page":"44","article-title":"Anti-VEGF drugs in the prevention of blindness","volume":"27","author":"Yorston","year":"2014","journal-title":"Community Eye Health"},{"key":"10.1016\/j.ymthe.2020.06.029_bib90","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2020.06.029_bib91","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/j.ophtha.2011.12.016","article-title":"HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration","volume":"119","author":"Singer","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ymthe.2020.06.029_bib95","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1136\/bjo.2007.134874","article-title":"Predicted biological activity of intravitreal VEGF Trap","volume":"92","author":"Stewart","year":"2008","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.ymthe.2020.06.029_bib96","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1517\/14728214.2014.884559","article-title":"Emerging treatments for wet age-related macular degeneration","volume":"19","author":"Smith","year":"2014","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"10.1016\/j.ymthe.2020.06.029_bib97","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1097\/00006982-200410000-00002","article-title":"Risks of intravitreous injection: a comprehensive review","volume":"24","author":"Jager","year":"2004","journal-title":"Retina"},{"key":"10.1016\/j.ymthe.2020.06.029_bib98","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/j.1442-9071.2009.02043.x","article-title":"Submacular haemorrhage after intravitreal bevacizumab compared with intravitreal ranibizumab in large occult choroidal neovascularization","volume":"37","author":"Krishnan","year":"2009","journal-title":"Clin. Exp. Ophthalmol."},{"key":"10.1016\/j.ymthe.2020.06.029_bib99","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1089\/jop.2009.0076","article-title":"Persistent ocular hypertension following intravitreal bevacizumab and ranibizumab injections","volume":"26","author":"Adelman","year":"2010","journal-title":"J.\u00a0Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.ymthe.2020.06.029_bib100","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1038\/nbt1117-998","article-title":"First AAV gene therapy poised for landmark approval","volume":"35","author":"Smalley","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2020.06.029_bib101","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.preteyeres.2018.08.003","article-title":"Gene therapy for visual loss: opportunities and concerns","volume":"68","author":"Lee","year":"2019","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.ymthe.2020.06.029_bib102","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/mt.2012.280","article-title":"A comprehensive review of retinal gene therapy","volume":"21","author":"Boye","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2020.06.029_bib103","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1016\/j.visres.2008.01.010","article-title":"Fundus autofluorescence imaging of retinal dystrophies","volume":"48","author":"Boon","year":"2008","journal-title":"Vision Res."},{"key":"10.1016\/j.ymthe.2020.06.029_bib104","doi-asserted-by":"crossref","first-page":"051403","DOI":"10.1117\/1.2793736","article-title":"Optical coherence tomography: a review of clinical development from bench to bedside","volume":"12","author":"Zysk","year":"2007","journal-title":"J.\u00a0Biomed. Opt."},{"key":"10.1016\/j.ymthe.2020.06.029_bib105","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/bmb\/ldy005","article-title":"Retinal gene therapy","volume":"126","author":"Kumaran","year":"2018","journal-title":"Br. Med. Bull."},{"key":"10.1016\/j.ymthe.2020.06.029_bib106","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1172\/JCI42440","article-title":"A look at autoimmunity and inflammation in the eye","volume":"120","author":"Caspi","year":"2010","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2020.06.029_bib107","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1172\/JCI120429","article-title":"Gene therapy and genome surgery in the retina","volume":"128","author":"DiCarlo","year":"2018","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2020.06.029_bib108","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.3389\/fphar.2019.01076","article-title":"Outcome measures used in ocular gene therapy trials: a scoping review of current practice","volume":"10","author":"Jolly","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ymthe.2020.06.029_bib109","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1136\/pgmj.2004.023309","article-title":"Angiogenesis: a curse or cure?","volume":"81","author":"Gupta","year":"2005","journal-title":"Postgrad. Med. J."},{"key":"10.1016\/j.ymthe.2020.06.029_bib110","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1159\/000434698","article-title":"Ocular gene therapy","volume":"55","author":"Campbell","year":"2016","journal-title":"Dev. Ophthalmol."},{"key":"10.1016\/j.ymthe.2020.06.029_bib111","doi-asserted-by":"crossref","first-page":"434","DOI":"10.2174\/15665232113136660007","article-title":"Biosafety of recombinant adeno-associated virus vectors","volume":"13","author":"Dismuke","year":"2013","journal-title":"Curr. Gene Ther."},{"key":"10.1016\/j.ymthe.2020.06.029_bib112","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/mt.2010.258","article-title":"Preclinical safety evaluation of AAV2-sFLT01\u2014a gene therapy for age-related macular degeneration","volume":"19","author":"Maclachlan","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2020.06.029_bib113","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1089\/humc.2014.067","article-title":"Preclinical safety evaluation of a recombinant AAV8 vector for X-linked retinoschisis after intravitreal administration in rabbits","volume":"25","author":"Marangoni","year":"2014","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"10.1016\/j.ymthe.2020.06.029_bib114","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1089\/hum.2019.144","article-title":"Ocular inflammatory response to intravitreal injection of adeno-associated virus vector: relative contribution of genome and capsid","volume":"31","author":"Timmers","year":"2020","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2020.06.029_bib115","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.preteyeres.2012.09.001","article-title":"Clinical applications of retinal gene therapy","volume":"32","author":"Lipinski","year":"2013","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.ymthe.2020.06.029_bib116","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3389\/fonc.2019.00297","article-title":"Gene therapy leaves a vicious cycle","volume":"9","author":"Goswami","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ymthe.2020.06.029_bib117","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/nm.3793","article-title":"Therapeutic genome editing: prospects and challenges","volume":"21","author":"Cox","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2020.06.029_bib118","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-3-319-63904-8_1","article-title":"Viral vectors, engineered cells and the CRISPR revolution","volume":"1016","author":"DiCarlo","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.ymthe.2020.06.029_bib119","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.csbj.2016.12.006","article-title":"Programmable genome editing tools and their regulation for efficient genome engineering","volume":"15","author":"Guha","year":"2017","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"10.1016\/j.ymthe.2020.06.029_bib120","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/nbt.2842","article-title":"CRISPR-Cas systems for editing, regulating and targeting genomes","volume":"32","author":"Sander","year":"2014","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2020.06.029_bib121","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1126\/science.1231143","article-title":"Multiplex genome engineering using CRISPR\/Cas systems","volume":"339","author":"Cong","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2020.06.029_bib122","doi-asserted-by":"crossref","first-page":"5400","DOI":"10.1038\/srep05400","article-title":"Multiplex genome engineering in human cells using all-in-one CRISPR\/Cas9 vector system","volume":"4","author":"Sakuma","year":"2014","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2020.06.029_bib123","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/s41576-018-0059-1","article-title":"Base editing: precision chemistry on the genome and transcriptome of living cells","volume":"19","author":"Rees","year":"2018","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.ymthe.2020.06.029_bib124","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/s41592-018-0146-4","article-title":"Base editing a CRISPR way","volume":"15","author":"Marx","year":"2018","journal-title":"Nat. Methods"},{"key":"10.1016\/j.ymthe.2020.06.029_bib125","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41586-019-1711-4","article-title":"Search-and-replace genome editing without double-strand breaks or donor DNA","volume":"576","author":"Anzalone","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2020.06.029_bib126","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/nature24049","article-title":"RNA targeting with CRISPR-Cas13","volume":"550","author":"Abudayyeh","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2020.06.029_bib127","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.cell.2018.02.033","article-title":"Transcriptome engineering with RNA-targeting type VI-D CRISPR effectors","volume":"173","author":"Konermann","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2020.06.029_bib128","doi-asserted-by":"crossref","first-page":"14716","DOI":"10.1038\/ncomms14716","article-title":"Nrl knockdown by AAV-delivered CRISPR\/Cas9 prevents retinal degeneration in mice","volume":"8","author":"Yu","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2020.06.029_bib129","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/mt.2015.220","article-title":"In\u00a0vivo CRISPR\/Cas9 gene editing corrects retinal dystrophy in the S334ter-3 rat model of autosomal dominant retinitis pigmentosa","volume":"24","author":"Bakondi","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2020.06.029_bib130","doi-asserted-by":"crossref","first-page":"6082","DOI":"10.1167\/iovs.17-21902","article-title":"AAV-CRISPR\/Cas9-mediated depletion of VEGFR2 blocks angiogenesis in\u00a0vitro","volume":"58","author":"Wu","year":"2017","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ymthe.2020.06.029_bib131","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1038\/s41467-018-04175-y","article-title":"CRISPR-LbCpf1 prevents choroidal neovascularization in a mouse model of age-related macular degeneration","volume":"9","author":"Koo","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2020.06.029_bib146","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1016\/S0140-6736(15)00345-1","article-title":"Gene therapy with recombinant adeno-associated vectors for neovascular age-related macular degeneration: 1 year follow-up of a phase 1 randomised clinical trial","volume":"386","author":"Rakoczy","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2020.06.029_bib230","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ebiom.2016.11.016","article-title":"Phase 2a randomized clinical trial: safety and post hoc analysis of subretinal rAAV.sFLT-1 for wet age-related macular degeneration","volume":"14","author":"Constable","year":"2016","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ymthe.2020.06.029_bib157","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1089\/hum.2016.117","article-title":"Lentiviral vector gene transfer of endostatin\/angiostatin for macular degeneration (GEM) study","volume":"28","author":"Campochiaro","year":"2017","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2020.06.029_bib143","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0140-6736(17)30979-0","article-title":"Intravitreous injection of AAV2-sFLT01 in patients with advanced neovascular age-related macular degeneration: a phase 1, open-label trial","volume":"390","author":"Heier","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2020.06.029_bib132","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1089\/hum.2006.17.167","article-title":"Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of a phase I clinical trial","volume":"17","author":"Campochiaro","year":"2006","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2020.06.029_bib184","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1016\/j.ophtha.2012.03.043","article-title":"Evaluation of the siRNA PF-04523655 versus ranibizumab for the treatment of neovascular age-related macular degeneration (MONET Study)","volume":"119","author":"Nguyen","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ymthe.2020.06.029_bib185","doi-asserted-by":"crossref","first-page":"7666","DOI":"10.1167\/iovs.12-9961","article-title":"Dose-ranging evaluation of intravitreal siRNA PF-04523655 for diabetic macular edema (the DEGAS study)","volume":"53","author":"Nguyen","year":"2012","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ymthe.2020.06.029_bib183","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1038\/eye.2012.106","article-title":"Phase 1 dose-escalation study of a siRNA targeting the RTP801 gene in age-related macular degeneration patients","volume":"26","author":"Nguyen","year":"2012","journal-title":"Eye (Lond.)"},{"key":"10.1016\/j.ymthe.2020.06.029_bib181","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ajo.2010.02.006","article-title":"RNAi-based treatment for neovascular age-related macular degeneration by Sirna-027","volume":"150","author":"Kaiser","year":"2010","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.ymthe.2020.06.029_bib133","first-page":"2535","article-title":"Adenovirus vector-mediated in\u00a0vivo gene transfer into adult murine retina","volume":"35","author":"Bennett","year":"1994","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ymthe.2020.06.029_bib134","doi-asserted-by":"crossref","first-page":"13565","DOI":"10.1073\/pnas.93.24.13565","article-title":"A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal","volume":"93","author":"Parks","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2020.06.029_bib135","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1126\/science.285.5425.245","article-title":"Pigment epithelium-derived factor: a potent inhibitor of angiogenesis","volume":"285","author":"Dawson","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2020.06.029_bib136","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/S0002-9394(02)01549-0","article-title":"Pigment epithelium-derived factor is deficient in the vitreous of patients with choroidal neovascularization due to age-related macular degeneration","volume":"134","author":"Holekamp","year":"2002","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.ymthe.2020.06.029_bib137","doi-asserted-by":"crossref","first-page":"23659","DOI":"10.1074\/jbc.272.38.23659","article-title":"Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes. Flt-1, but not Flk-1\/KDR, is up-regulated by hypoxia","volume":"272","author":"Gerber","year":"1997","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ymthe.2020.06.029_bib138","doi-asserted-by":"crossref","first-page":"10705","DOI":"10.1073\/pnas.90.22.10705","article-title":"Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor","volume":"90","author":"Kendall","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2020.06.029_bib139","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1006\/bbrc.1996.1355","article-title":"Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR","volume":"226","author":"Kendall","year":"1996","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ymthe.2020.06.029_bib140","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.ymthe.2005.04.022","article-title":"Long-term evaluation of AAV-mediated sFlt-1 gene therapy for ocular neovascularization in mice and monkeys","volume":"12","author":"Lai","year":"2005","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2020.06.029_bib141","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/mt.2010.230","article-title":"Inhibition of choroidal neovascularization in a nonhuman primate model by intravitreal administration of an AAV2 vector expressing a novel anti-VEGF molecule","volume":"19","author":"Lukason","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2020.06.029_bib142","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1038\/gt.2011.169","article-title":"Preclinical safety evaluation of subretinal AAV2.sFlt-1 in non-human primates","volume":"19","author":"Lai","year":"2012","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2020.06.029_bib144","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ajo.2019.03.006","article-title":"Three-year follow-up of phase 1 and 2a rAAV.sFLT-1 subretinal gene therapy trials for exudative age-related macular degeneration","volume":"204","author":"Rakoczy","year":"2019","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.ymthe.2020.06.029_bib145","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ajo.2017.02.018","article-title":"Gene therapy in neovascular age-related macular degeneration: three-year follow-up of a phase 1 randomized dose escalation trial","volume":"177","author":"Constable","year":"2017","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.ymthe.2020.06.029_bib147","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ymthe.2018.11.003","article-title":"Preclinical evaluation of ADVM-022, a novel gene therapy approach to treating wet age-related macular degeneration","volume":"27","author":"Grishanin","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2020.06.029_bib148","author":"Adverum Biotechnologies"},{"key":"10.1016\/j.ymthe.2020.06.029_bib150","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0092-8674(00)81848-6","article-title":"Endostatin: an endogenous inhibitor of angiogenesis and tumor growth","volume":"88","author":"O\u2019Reilly","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2020.06.029_bib151","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/0092-8674(94)90200-3","article-title":"Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma","volume":"79","author":"O\u2019Reilly","year":"1994","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2020.06.029_bib152","first-page":"2344","article-title":"Subconjunctival injection of recombinant AAV-angiostatin ameliorates alkali burn induced corneal angiogenesis","volume":"13","author":"Cheng","year":"2007","journal-title":"Mol. Vis."},{"key":"10.1016\/j.ymthe.2020.06.029_bib153","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/sj.gt.3301878","article-title":"Lentivirus-mediated expression of angiostatin efficiently inhibits neovascularization in a murine proliferative retinopathy model","volume":"10","author":"Igarashi","year":"2003","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2020.06.029_bib154","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s11373-007-9153-7","article-title":"Inhibition of corneal neovascularization with endostatin delivered by adeno-associated viral (AAV) vector in a mouse corneal injury model","volume":"14","author":"Lai","year":"2007","journal-title":"J.\u00a0Biomed. Sci."},{"key":"10.1016\/j.ymthe.2020.06.029_bib155","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1089\/hum.2008.046","article-title":"Equine infectious anemia viral vector-mediated codelivery of endostatin and angiostatin driven by retinal pigmented epithelium-specific VMD2 promoter inhibits choroidal neovascularization","volume":"20","author":"Kachi","year":"2009","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2020.06.029_bib156","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1038\/sj.gt.3302769","article-title":"EIAV vector-mediated delivery of endostatin or angiostatin inhibits angiogenesis and vascular hyperpermeability in experimental CNV","volume":"13","author":"Balaggan","year":"2006","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2020.06.029_bib158","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.preteyeres.2009.11.003","article-title":"The pivotal role of the complement system in aging and age-related macular degeneration: hypothesis re-visited","volume":"29","author":"Anderson","year":"2010","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.ymthe.2020.06.029_bib159","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.exer.2019.05.006","article-title":"The role of complement membrane attack complex in dry and wet AMD\u2014from hypothesis to clinical trials","volume":"184","author":"Kumar-Singh","year":"2019","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.ymthe.2020.06.029_bib160","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.4049\/jimmunol.144.9.3478","article-title":"The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9","volume":"144","author":"Rollins","year":"1990","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ymthe.2020.06.029_bib161","first-page":"34","article-title":"Recombinant soluble CD59 inhibits reactive haemolysis with complement","volume":"82","author":"Sugita","year":"1994","journal-title":"Immunology"},{"key":"10.1016\/j.ymthe.2020.06.029_bib162","doi-asserted-by":"crossref","first-page":"48921","DOI":"10.1074\/jbc.M302598200","article-title":"Generation of a recombinant, membrane-targeted form of the complement regulator CD59: activity in\u00a0vitro and in\u00a0vivo","volume":"278","author":"Fraser","year":"2003","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ymthe.2020.06.029_bib163","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/nrg908","article-title":"Gene silencing in mammals by small interfering RNAs","volume":"3","author":"McManus","year":"2002","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.ymthe.2020.06.029_bib164","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.bbrc.2012.08.128","article-title":"siRNAs conjugated with aromatic compounds induce RISC-mediated antisense strand selection and strong gene-silencing activity","volume":"426","author":"Kubo","year":"2012","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ymthe.2020.06.029_bib165","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/sj.gt.3302641","article-title":"Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1","volume":"13","author":"Shen","year":"2006","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2020.06.029_bib166","first-page":"210","article-title":"Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model","volume":"9","author":"Reich","year":"2003","journal-title":"Mol. Vis."},{"key":"10.1016\/j.ymthe.2020.06.029_bib167","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1097\/00006982-200408000-00039","article-title":"Intravitreal injection of vascular endothelial growth factor small interfering RNA inhibits growth and leakage in a nonhuman primate, laser-induced model of choroidal neovascularization","volume":"24","author":"Tolentino","year":"2004","journal-title":"Retina"},{"key":"10.1016\/j.ymthe.2020.06.029_bib168","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3109\/02713681003597230","article-title":"A siRNA targeting vascular endothelial growth factor-A inhibiting experimental corneal neovascularization","volume":"35","author":"Zuo","year":"2010","journal-title":"Curr. Eye Res."},{"key":"10.1016\/j.ymthe.2020.06.029_bib169","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/ICO.0b013e31802b4201","article-title":"Unique homologous siRNA blocks hypoxia-induced VEGF upregulation in human corneal cells and inhibits and regresses murine corneal neovascularization","volume":"26","author":"Singh","year":"2007","journal-title":"Cornea"},{"key":"10.1016\/j.ymthe.2020.06.029_bib170","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/nature07758","article-title":"The promises and pitfalls of RNA-interference-based therapeutics","volume":"457","author":"Castanotto","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2020.06.029_bib171","doi-asserted-by":"crossref","first-page":"75","DOI":"10.4137\/OED.S4878","article-title":"Bevasiranib for the treatment of wet, age-related macular degeneration","volume":"2","author":"Garba","year":"2010","journal-title":"Ophthalmol. Eye Dis."},{"key":"10.1016\/j.ymthe.2020.06.029_bib172","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1159\/000320008","article-title":"Antivascular endothelial growth factor in diabetic retinopathy","volume":"46","author":"Iacono","year":"2010","journal-title":"Dev. Ophthalmol."},{"key":"10.1016\/j.ymthe.2020.06.029_bib173","series-title":"Therapy for Ocular Angiogenesis: Principles and Practice","first-page":"154","article-title":"Anti-VEGF therapies in diabetic macular edema","author":"Silva","year":"2011"},{"key":"10.1016\/j.ymthe.2020.06.029_bib174","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1111\/bph.12330","article-title":"Small-interfering RNAs (siRNAs) as a promising tool for ocular therapy","volume":"170","author":"Guzman-Aranguez","year":"2013","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ymthe.2020.06.029_bib175","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1089\/hum.2015.064","article-title":"Antiangiogenic eye gene therapy","volume":"26","author":"Corydon","year":"2015","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2020.06.029_bib176","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/nature06765","article-title":"Sequence- and target-independent angiogenesis suppression by siRNA via TLR3","volume":"452","author":"Kleinman","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2020.06.029_bib177","doi-asserted-by":"crossref","first-page":"7137","DOI":"10.1073\/pnas.0812317106","article-title":"Small interfering RNA-induced TLR3 activation inhibits blood and lymphatic vessel growth","volume":"106","author":"Cho","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2020.06.029_bib178","doi-asserted-by":"crossref","first-page":"3820","DOI":"10.1167\/iovs.09-5121","article-title":"Suppression of laser-induced choroidal neovascularization by nontargeted siRNA","volume":"51","author":"Ashikari","year":"2010","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ymthe.2020.06.029_bib179","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.exer.2010.06.019","article-title":"Inhibition of experimental choroidal neovascularization in mice by anti-VEGFA\/VEGFR2 or non-specific siRNA","volume":"91","author":"Gu","year":"2010","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.ymthe.2020.06.029_bib180","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/mt.2011.212","article-title":"Short-interfering RNAs induce retinal degeneration via TLR3 and IRF3","volume":"20","author":"Kleinman","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2020.06.029_bib182","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.immuni.2005.06.008","article-title":"Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA","volume":"23","author":"Karik\u00f3","year":"2005","journal-title":"Immunity"},{"key":"10.1016\/j.ymthe.2020.06.029_bib186","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1126\/science.1073827","article-title":"A microRNA in a multiple-turnover RNAi enzyme complex","volume":"297","author":"Hutv\u00e1gner","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2020.06.029_bib187","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1167\/iovs.05-1610","article-title":"Inhibition of choroidal neovascularization by adenovirus-mediated delivery of short hairpin RNAs targeting VEGF as a potential therapy for AMD","volume":"47","author":"Cashman","year":"2006","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ymthe.2020.06.029_bib188","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1002\/jgm.2678","article-title":"Reduction of choroidal neovascularization in mice by adeno-associated virus-delivered anti-vascular endothelial growth factor short hairpin RNA","volume":"14","author":"Askou","year":"2012","journal-title":"J.\u00a0Gene Med."},{"key":"10.1016\/j.ymthe.2020.06.029_bib189","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.omtn.2018.11.013","article-title":"Efficient knockdown and lack of passenger strand activity by Dicer-independent shRNAs expressed from Pol II-driven microRNA scaffolds","volume":"14","author":"Kaadt","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ymthe.2020.06.029_bib190","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/978-1-4939-7522-8_4","article-title":"Development of multigenic lentiviral vectors for cell-specific expression of antiangiogenic miRNAs and protein factors","volume":"1715","author":"Askou","year":"2018","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ymthe.2020.06.029_bib191","doi-asserted-by":"crossref","first-page":"14064","DOI":"10.1038\/mtm.2014.64","article-title":"Multigenic lentiviral vectors for combined and tissue-specific expression of miRNA- and protein-based antiangiogenic factors","volume":"2","author":"Askou","year":"2015","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2020.06.029_bib192","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.omtn.2019.01.012","article-title":"Suppression of choroidal neovascularization by AAV-based dual-acting antiangiogenic gene therapy","volume":"16","author":"Askou","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ymthe.2020.06.029_bib193","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41591-018-0327-9","article-title":"Development of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10","volume":"25","author":"Maeder","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2020.06.029_bib194","doi-asserted-by":"crossref","first-page":"8366","DOI":"10.1038\/srep08366","article-title":"CRISPR-engineered mosaicism rapidly reveals that loss of Kcnj13 function in mice mimics human disease phenotypes","volume":"5","author":"Zhong","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2020.06.029_bib231","doi-asserted-by":"crossref","first-page":"5490","DOI":"10.1167\/iovs.16-20296","article-title":"Genomic disruption of VEGF-A expression in human retinal pigment epithelial cells using CRISPR-Cas9 endonuclease","volume":"57","author":"Yiu","year":"2016","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ymthe.2020.06.029_bib232","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1167\/iovs.16-20537","article-title":"Editing VEGFR2 blocks VEGF-induced activation of Akt and tube formation","volume":"58","author":"Huang","year":"2017","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ymthe.2020.06.029_bib195","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41467-017-00140-3","article-title":"Genome editing abrogates angiogenesis in\u00a0vivo","volume":"8","author":"Huang","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2020.06.029_bib196","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.omtn.2017.08.016","article-title":"In\u00a0vivo knockout of the Vegfa gene by lentiviral delivery of CRISPR\/Cas9 in mouse retinal pigment epithelium cells","volume":"9","author":"Holmgaard","year":"2017","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ymthe.2020.06.029_bib206","doi-asserted-by":"crossref","first-page":"14500","DOI":"10.1038\/ncomms14500","article-title":"In\u00a0vivo genome editing with a small Cas9 orthologue derived from Campylobacter jejuni","volume":"8","author":"Kim","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2020.06.029_bib211","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ymthe.2018.10.009","article-title":"Long-term effects of in\u00a0vivo genome editing in the mouse retina using Campylobacter jejuni Cas9 expressed via adeno-associated virus","volume":"27","author":"Jo","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2020.06.029_bib217","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1101\/gr.219089.116","article-title":"Genome surgery using Cas9 ribonucleoproteins for the treatment of age-related macular degeneration","volume":"27","author":"Kim","year":"2017","journal-title":"Genome Res."},{"key":"10.1016\/j.ymthe.2020.06.029_bib197","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.12688\/f1000research.11243.1","article-title":"In\u00a0vivo genome editing in animals using AAV-CRISPR system: applications to translational research of human disease","volume":"6","author":"Lau","year":"2017","journal-title":"F1000Res."},{"key":"10.1016\/j.ymthe.2020.06.029_bib198","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/nature13579","article-title":"Structural basis of PAM-dependent target DNA recognition by the Cas9 endonuclease","volume":"513","author":"Anders","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2020.06.029_bib199","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ymthe.2018.12.007","article-title":"AAV-CRISPR persistence in the eye of the beholder","volume":"27","author":"Recchia","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2020.06.029_bib200","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/sj.gt.3302485","article-title":"Lentiviral vector-mediated gene transfer in adult mouse photoreceptors is impaired by the presence of a physical barrier","volume":"12","author":"Gr\u00fcter","year":"2005","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2020.06.029_bib201","doi-asserted-by":"crossref","first-page":"4061","DOI":"10.1167\/iovs.13-11871","article-title":"Transduction of photoreceptors with equine infectious anemia virus lentiviral vectors: safety and biodistribution of StarGen for Stargardt disease","volume":"54","author":"Binley","year":"2013","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ymthe.2020.06.029_bib202","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/nbt.3469","article-title":"A dual AAV system enables the Cas9-mediated correction of a metabolic liver disease in newborn mice","volume":"34","author":"Yang","year":"2016","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2020.06.029_bib203","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/nbt.3149","article-title":"A split-Cas9 architecture for inducible genome editing and transcription modulation","volume":"33","author":"Zetsche","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2020.06.029_bib204","doi-asserted-by":"crossref","first-page":"6450","DOI":"10.1093\/nar\/gkv601","article-title":"Development of an intein-mediated split-Cas9 system for gene therapy","volume":"43","author":"Truong","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2020.06.029_bib205","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/nature14299","article-title":"In\u00a0vivo genome editing using Staphylococcus aureus Cas9","volume":"520","author":"Ran","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2020.06.029_bib207","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1038\/mt.2015.218","article-title":"Streptococcus thermophilus CRISPR-Cas9 systems enable specific editing of the human genome","volume":"24","author":"M\u00fcller","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2020.06.029_bib208","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.cell.2015.09.038","article-title":"Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system","volume":"163","author":"Zetsche","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2020.06.029_bib209","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/emmm.201302948","article-title":"Effective delivery of large genes to the retina by dual AAV vectors","volume":"6","author":"Trapani","year":"2014","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.ymthe.2020.06.029_bib210","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1073\/pnas.1501698112","article-title":"Rational design of a split-Cas9 enzyme complex","volume":"112","author":"Wright","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2020.06.029_bib212","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1038\/nbt.3609","article-title":"Genome-wide analysis reveals specificities of Cpf1 endonucleases in human cells","volume":"34","author":"Kim","year":"2016","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2020.06.029_bib213","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/nbt.3620","article-title":"Genome-wide specificities of CRISPR-Cas Cpf1 nucleases in human cells","volume":"34","author":"Kleinstiver","year":"2016","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2020.06.029_bib214","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/nbt.2623","article-title":"High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells","volume":"31","author":"Fu","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2020.06.029_bib215","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/nbt.2673","article-title":"High-throughput profiling of off-target DNA cleavage reveals RNA-programmed Cas9 nuclease specificity","volume":"31","author":"Pattanayak","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2020.06.029_bib216","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/nmeth.3993","article-title":"A multifunctional AAV-CRISPR-Cas9 and its host response","volume":"13","author":"Chew","year":"2016","journal-title":"Nat. Methods"},{"key":"10.1016\/j.ymthe.2020.06.029_bib218","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1101\/gr.171322.113","article-title":"Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins","volume":"24","author":"Kim","year":"2014","journal-title":"Genome Res."},{"key":"10.1016\/j.ymthe.2020.06.029_bib219","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/nature16526","article-title":"High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects","volume":"529","author":"Kleinstiver","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2020.06.029_bib220","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1126\/science.aad5227","article-title":"Rationally engineered Cas9 nucleases with improved specificity","volume":"351","author":"Slaymaker","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2020.06.029_bib221","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/nature24268","article-title":"Enhanced proofreading governs CRISPR-Cas9 targeting accuracy","volume":"550","author":"Chen","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2020.06.029_bib222","doi-asserted-by":"crossref","first-page":"e1701620","DOI":"10.1126\/sciadv.1701620","article-title":"Disabling Cas9 by an anti-CRISPR DNA mimic","volume":"3","author":"Shin","year":"2017","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ymthe.2020.06.029_bib223","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/nbt.3155","article-title":"Inducible in\u00a0vivo genome editing with CRISPR-Cas9","volume":"33","author":"Dow","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2020.06.029_bib224","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1016\/j.celrep.2017.08.075","article-title":"The self-inactivating KamiCas9 system for the editing of CNS disease genes","volume":"20","author":"Merienne","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.ymthe.2020.06.029_bib225","doi-asserted-by":"crossref","first-page":"15334","DOI":"10.1038\/ncomms15334","article-title":"Hit and go CAS9 delivered through a lentiviral based self-limiting circuit","volume":"8","author":"Petris","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2020.06.029_bib226","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.omtm.2018.11.009","article-title":"A self-deleting AAV-CRISPR ysstem for in\u00a0vivo genome editing","volume":"12","author":"Li","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001620303415?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001620303415?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T20:05:18Z","timestamp":1778616318000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001620303415"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":229,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S1525001620303415"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2020.06.029","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gene Therapy Intervention in Neovascular Eye Disease: A Recent Update","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2020.06.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}